The access issues that are hampering sales growth for AstraZeneca PLC's Evusheld, are firmly in the spotlight again with the UK government's decision not to buy the antibody cocktail for the prevention of COVID-19 being described as irrenponsible and nonsense.
Anger Over Access To AstraZeneca's Evusheld Peaks In UK
Sales Of COVID-19 Antibody Have Slowed
News that the UK government will not procur any doses of AstraZeneca’s Evusheld for the prevention of COVID-19 infections in immunocompromised people has been greeted with dismay and the move will hurt the combo's already-limited sales growth.
More from COVID-19
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.